3211-76-5
3211-76-5 結(jié)構(gòu)式
基本信息
硒代蛋氨酸
L-(+)-硒代蛋氨酸
(S)-(+)-2-氨基-4-(甲基硒)丁酸
L-(+)-2-AMINO-4-(METHYLSELENO)BUTANOIC ACID
L-(+)-SELENOMETHIONINE
L-SELENOMETHIONINE
(S)-(+)-2-AMINO-4-(METHYLSELENO)BUTANOIC ACID
(S)-2-AMINO-4-(METHYLSELENO)BUTYRIC ACID
SELENO-L-METHIONINE
SELENOMETHIONINE, L-(+)-
SEMET
L(+)-SELENOMETHIONINE 99+% E.E.
(S)-2-AMINO-4-(METHYLSELENYL)BUTYRIC ACID
L(+)-Selenomethionine, ee 99+%, 99+%
Butanoic acid, 2-amino-4-(methylseleno)-, (2S)-
L-SELENOMETHIONINE SELENO-L-METHIONINE L-SE-MET-OH
L-selenomethionine （L-se-Met-OH）
BUTYRICACID,2-AMINO-4-(METHYLSELENYL)-,L-
L-SELENOMETHIONINE 0.5%
L-SELENOMETHIONINE USP
THALLIUM ETHYLSUFATE
(S)-(+)-2-Amino-4-(methylseleno)butanoic acid, (S)-2-Amino-4-(methylseleno)butyric acid, L-Selenomethionine, Seleno-L-methionine
物理化學(xué)性質(zhì)
安全數(shù)據(jù)
very toxic hazardous materials
Acute Tox. 3 Oral
Aquatic Acute 1
Aquatic Chronic 1
STOT RE 2
應(yīng)用領(lǐng)域
制備方法
2185-03-7
37773-10-7
3211-76-5
在氮?dú)獗Ｗo(hù)下，將13.75 g L-高絲氨酸內(nèi)酯鹽酸鹽與40 mL N,N-二甲基甲酰胺(DMF)混合，攪拌至完全溶解。隨后，將15.2 g硒酸甲酯（CAS:37773-10-7）溶于20 mL DMF中，緩慢加入上述反應(yīng)體系。加熱回流反應(yīng)2小時。反應(yīng)完成后，用乙酸水溶液調(diào)節(jié)反應(yīng)體系的pH至6.0，析出白色固體。將所得固體溶于水和乙醇的混合溶劑中進(jìn)行重結(jié)晶，得到L-硒代蛋氨酸。該合成路線的總收率為72.11%，產(chǎn)物的化學(xué)純度大于99%，對映體過量值(ee)大于99%。
參考文獻(xiàn)：
[1] Patent: CN106928110, 2017, A. Location in patent: Paragraph 0028; 0030
知名試劑公司產(chǎn)品信息
L(+)-Selenomethionine, ee 99+%, 99+%(3211-76-5)
L-Selenomethionine,>98.0%(T)(3211-76-5)
| 報價日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價格 |
| 2026/03/03 | 25996 | L(+)硒代蛋氨酸 L(+)-Selenomethionine, 99+%, ee 99+% | 3211-76-5 | 250mg | 2813元 |
| 2026/03/03 | S3973 | L-硒代蛋氨酸 L-SelenoMethionine | 3211-76-5 | 25mg | 795.39元 |
| 2026/03/03 | S3973 | L-硒代蛋氨酸 L-SelenoMethionine | 3211-76-5 | 1g | 4013.1元 |
常見問題列表
|
Human Endogenous Metabolite
|
L-SelenoMethionine (1-500 μM; 24-72 h) is selectively inhibits the growth of prostate cancer cells, compared with normal cells.
L-SelenoMethionine (500 μM; 48 h) induce apoptosis in prostate cancer cells.
L-SelenoMethionine (500 μM; 48 h) causes an increase in arrest in the G2-M phase of the cell cycle selectively in prostate cancer cells.
L-SelenoMethionine (5 μM; 24 h) mitigates gene expression associated with the cellular stress response from 10 cGy irradiation.
Cell Viability Assay
| Cell Line: | Prostate cancer cells (LNCaP, PC-3, and DU145) and normal prostate cells (PrEC, PrSM, and PrSt) |
| Concentration: | 1, 5, 10, 50, 100, 500 μM |
| Incubation Time: | 24, 48, 72 hours |
| Result: | Inhibited the growth of prostate cancer cells, with a lower IC 50 (1-90 μM) at 72 h than normal prostate cells (>500 μM). |
Apoptosis Analysis
| Cell Line: | Prostate cancer cells (LNCaP, PC-3, and DU145) and normal prostate cells (PrEC, PrSM, and PrSt) |
| Concentration: | 500 μM |
| Incubation Time: | 48 hours |
| Result: |
Exhibited the highest level of DNA condensation in androgen-responsive LNCaP carcinoma cells, followed by PC-3 and DU145 cells.
Exhibited the nicked-end DNA labeling in prostate cancer cells. Promoted the PARP cleavage in prostate cancer cells. |
Cell Cycle Analysis
| Cell Line: | Prostate cancer cells (LNCaP, PC-3, and DU145) and normal prostate cells (PrEC, PrSM, and PrSt) |
| Concentration: | 500 μM |
| Incubation Time: | 48 hours |
| Result: |
Increased the sub-G0-G1 cell fraction of LNCaP (41.5%), PC-3 (12.1%), and DU145 cells (11.2%).
Caused a significant increases in G2 cells , particularly in LNCaP (13%), PC-3 (32%), and DU145 (20%) cells. |
RT-PCR
| Cell Line: | Human thyroid epithelial cells (HTori-3) |
| Concentration: | 5 μM |
| Incubation Time: | 24 hours |
| Result: | Downregulated the CDC6, GADD45A, FAS and ATF3 in irradiated cells. |
L-SelenoMethionine (0.06-12 μg/g diet; p.o. for 3 d) partially or completely prevent the decrease in the serum or plasma levels of total antioxidants in rats exposed to gamma rays, protons or HZE particles.